Rubicon Research FY26 Results: Profit Hits ₹246.74 Cr, Dividend Recommended

Rubicon Research Limited reported a consolidated net profit of ₹246.74 crore for the fiscal year ended March 31, 2026, on consolidated revenue from operations of ₹1,753.96 crore.

Reader Takeaway: Strong FY26 performance and strategic acquisition offset by remaining IPO proceeds.

What just happened

Rubicon Research announced its financial results for the fourth quarter and full fiscal year 2026. The company posted a consolidated net profit of ₹246.74 crore for the year, a significant increase from its consolidated revenue of ₹1,753.96 crore. For the fourth quarter ended March 31, 2026, the consolidated net profit was ₹76.79 crore on a revenue of ₹513.92 crore.

The company also recommended a final dividend of ₹1.50 per equity share. A major strategic move was the acquisition of a 65% stake in Amna Lifesciences Limited for ₹175.92 crore, completed on April 30, 2026.

Why this matters

The strong financial performance for FY26 indicates robust business operations and growth. The recommended dividend offers a direct return to shareholders. The acquisition of Amna Lifesciences signals a strategic push for inorganic growth, potentially expanding the company's market presence and product portfolio.

The backstory

Rubicon Research had previously raised funds through an IPO. As of March 31, 2026, ₹323.65 crore of IPO proceeds had been utilized, with ₹147.63 crore remaining. The company operates with an unmodified audit opinion from Deloitte Haskins & Sells LLP, ensuring a clean financial reporting record. In January 2026, GST authorities conducted an inspection, but no adverse findings or notices were issued.

What changes now

The acquisition of Amna Lifesciences is expected to contribute to future growth and profitability. Investors will be watching how the remaining IPO funds are deployed. The dividend payout will provide immediate value to shareholders.

Risks to watch

Potential risks include the successful integration of Amna Lifesciences and the effective utilization of the remaining IPO proceeds. While a GST inspection occurred, the absence of a show-cause notice is positive, but ongoing regulatory scrutiny is always a factor.

Peer comparison

While specific peer financial data for the same period isn't provided in the filing, Rubicon Research's performance needs to be assessed against other pharmaceutical and research companies in India. Competitors typically focus on R&D, manufacturing, and market expansion. Rubicon's strategy with Amna Lifesciences suggests a focus on expanding its footprint in the life sciences sector.

Context metrics (time-bound)

• FY2026 Consolidated Revenue: ₹1,753.96 crore
• FY2026 Consolidated Net Profit: ₹246.74 crore
• Q4 FY2026 Consolidated Revenue: ₹513.92 crore
• Q4 FY2026 Consolidated Net Profit: ₹76.79 crore
• Dividend Recommended: ₹1.50 per equity share
• Amna Lifesciences Acquisition: 65% stake for ₹175.92 crore
• Unutilized IPO Proceeds (as of Mar 31, 2026): ₹147.63 crore
• Incremental Employee Benefit Cost (New Labour Codes): ₹2.65 crore

What to track next

Investors should monitor the performance and integration of Amna Lifesciences, the utilization of the remaining IPO funds, and future dividend announcements. The company's ability to leverage its R&D strengths and expand market reach will be key indicators.